Table 3 Univariate and multivariate analyses of OS and PFS.

From: Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab

Variable

OS

PFS

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

HR

95% CI

p value

Age (< 65 vs. > 65)

1.05

0.53–2.06

0.8893

   

0.84

0.48–1.49

0.5561

   

Sex (female vs. male)

1.05

0.49–2.28

0.8958

   

0.81

0.42–1.59

0.5505

   

ECOG PS (0–1 vs. > 2)

0.35

0.15–0.80

0.0126

0.37

0.15–0.86

0.0207

0.47

0.24–0.94

0.0323

0.61

0.29–1.28

0.1919

BMI (< 20.18 vs. > 20.18)

1.41

0.75–2.61

0.2779

   

0.88

0.52–1.47

0.6186

   

Disease status

 Locoregional recurrence

1

     

1

     

 Distant metastasis

1.82

0.96–3.43

0.0649

   

1.93

0.94–3.99

0.0748

   

 Recurrent and metastatic

1.21

0.34–4.26

0.7690

   

1.17

0.25–5.38

0.8427

   

 CPS (> 20 vs. < 20)

1.02

0.55–1.89

0.9437

   

1.21

0.71–2.03

0.4765

   

 CAR (< 0.3 vs. > 0.3)

0.53

0.30–1.02

0.0577

   

0.53

0.31–0.91

0.0199

0.85

0.45–1.61

0.6149

 NLR (< 5 vs. > 5)

0.38

0.20–0.73

0.0036

0.39

0.21–0.75

0.0049

0.42

0.25–0.72

0.0015

0.48

0.26–0.89

0.0216

  1. CAR, C-reactive protein-to-albumin ratio; NLR, Neutrophil-to-lymphocyte ratio.
  2. Significant values are in bold.
Back to article page